Antithrombin III Deficiency
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
GrifolsNEW YORK, NY
2 programs1
1
Plasma-derived AT-III concentratePhase 2/31 trial
Antithrombin IIIPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
OctapharmaAtenativ
GrifolsPlasma-derived AT-III concentrate
GrifolsAntithrombin III
Clinical Trials (3)
Atenativ Effect on Uterine Blood Flow and Preeclampsia
Start: Jan 2016Est. completion: May 20170
Phase 4Withdrawn
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
Start: Jan 2006Est. completion: Mar 2029
Phase 2/3Active Not Recruiting
Antithrombin III in Infectious Disease Caused by COVID-19
Start: Jul 2021Est. completion: Mar 2022
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space